European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations

Ultra-high purity surfactant for biologics and parenteral drug formulations

AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials

Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing

ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub

ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity

Evonik and Ethris partner to expand offerings for nucleic acid delivery

Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease

Congruence gets $32 million financing to advance genetic obesity candidate drug

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity